{
    "clinical_study": {
        "@rank": "18330", 
        "arm_group": {
            "arm_group_label": "Main", 
            "arm_group_type": "Experimental", 
            "description": "MVA HIV-B"
        }, 
        "brief_summary": {
            "textblock": "24 healthy male and female volunteers who are at low risk of HIV infection and entered into\n      the RISVAC02 study and were randomly allocated to receive 3 intramuscular injections of\n      MVA-B at weeks 0, 4 and 16 will receive a boosting dose 4 years thereafter.\n\n      Participants will attend one of two clinical centres on at least 5 occasions over 16 weeks.\n      These visits will comprise:\n\n        -  Screening\n\n        -  Trial entry and boosting immunisation\n\n        -  Early follow-up after immunisation\n\n        -  Follow-up x 2 including the final visit Participants will have blood and urine\n           collected, and receive 1 immunisation. They will be counselled prior to and following a\n           HIV test, and given health education on prevention of sexually transmitted infections\n           including HIV. T\n\n      The two centres which participate are:\n\n        -  Hospital Clinic, Barcelona and\n\n        -  Hospital Gregorio Mara\u00f1\u00f3n, Madrid The primary objective is to explore the safety and\n           immunogenicity of MVA-B."
        }, 
        "brief_title": "Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  male or female\n\n          -  age between 18 and 55 years on the day of screening\n\n          -  available for follow-up for the duration of the study (52 weeks from screening)\n\n          -  able to give written informed consent\n\n          -  at low risk of HIV and willing to remain so for the duration of the study low risk of\n             HIV infection defined as: no history of injecting drug use in the previous ten years\n             no gonorrhoea or syphilis in the last six months no high risk partner (e.g. injecting\n             drug use, HIV positive partner) either currently or within the past six months no\n             unprotected anal intercourse in the last six months no unprotected vaginal\n             intercourse outside a relationship with a regular known/presumed HIV negative partner\n             in the last six months\n\n          -  willing to undergo a HIV test\n\n          -  willing to undergo a genital infection screen\n\n          -  if heterosexually active female, using an effective method of contraception with\n             partner (combined oral contraceptive pill; injectable contraceptive; IUCD; consistent\n             record with condoms if using these; physiological or anatomical sterility in self or\n             partner) from 14 days prior to the first vaccination until 4 months after the last,\n             and willing to undergo urine pregnancy tests prior to each vaccination\n\n          -  if heterosexually active male, using an effective method of contraception with their\n             partner from the first day of vaccination until 4 months after the last vaccination\n\n        Exclusion Criteria:\n\n          -  positive for hepatitis B surface antigen, hepatitis C antibody, antibody responses to\n             vaccinia or serology indicating active syphilis requiring treatment\n\n          -  pregnant or lactating\n\n          -  clinically relevant abnormality on history or examination including history of\n             grand-mal epilepsy, severe eczema, immunodeficiency or use of immunosuppressives in\n             preceding 3 months\n\n          -  receipt of live attenuated vaccine within 60 days or other vaccine within 14 days of\n             enrolment\n\n          -  receipt of blood products or immunoglobin within 4 months of screening\n\n          -  participation in another trial of a medicinal product, completed less than  30 days\n             prior to enrolment\n\n          -  history of severe local or general reaction to vaccination defined as local:\n             extensive, indurated redness and swelling involving most of the front-lateral thigh\n             or the major circumference of the arm, not resolving within 72 hours general: fever\n             >= 39.5oC within 48 hours; anaphylaxis; bronchospasm; laryngeal\n\n          -  HIV 1/2 positive or indeterminate on screening\n\n          -  positive for hepatitis B surface antigen, hepatitis C antibody or serology indicating\n             active syphilis requiring treatment\n\n          -  grade 1 routine laboratory parameters\n\n          -  unlikely to comply with protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01923610", 
            "org_study_id": "RisVac02 boost"
        }, 
        "intervention": {
            "arm_group_label": "Main", 
            "description": "Biological/Vaccine: MVA-B Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)\n-~ 1 x 10e8 pfu/ml 3 immunisations at week 0, 4 and 16", 
            "intervention_name": "Experimental", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Low risk HIV infection", 
            "HIV Seronegativity", 
            "HIV Preventive Vaccine"
        ], 
        "lastchanged_date": "August 14, 2013", 
        "location": [
            {
                "contact": {
                    "email": "fgarcia@clinic.ub.es", 
                    "last_name": "Felipe Garcia, MD", 
                    "phone": "+34 93 227 54 00"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalunya", 
                        "zip": "08036"
                    }, 
                    "name": "Hospital Cl\u00ednic i Provincial de Barcelona"
                }, 
                "investigator": {
                    "last_name": "Felipe Garcia, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28007"
                    }, 
                    "name": "Hospital Universitario Gregorio Mara\u00f1\u00f3n"
                }, 
                "investigator": {
                    "last_name": "Juan Carlos L\u00f3pez Bernaldo de Quir\u00f3s, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B", 
        "overall_contact": {
            "last_name": "Felipe Garcia, MD", 
            "phone": "932275400"
        }, 
        "overall_official": {
            "affiliation": "Hospital Cl\u00ednic i Provincial de Barcelona", 
            "last_name": "Felipe Garcia, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Grade 3 or above local adverse event (pain, cutaneous reactions including induration)", 
                "measure": "Local adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Grade 3 or above systemic adverse event (temperature, chills, headache, nausea, vomiting, malaise, and myalgia)", 
                "measure": "Grade 3 or above systemic adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Grade 3 or above other clinical or laboratory adverse event confirmed at examination or on repeat testing respectively", 
                "measure": "Grade 3 or above other clinical or laboratory adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Any event attributable to vaccine leading to discontinuation of the immunisation regimen", 
                "measure": "Event attributable to vaccine leading to discontinuation", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "The primary immunogenicity parameters will be quantitative or present/absent, and are cellular responses - CD8/CD4+ T cell responses (ELISPOT) at week 2, 4 and 12 following the immunisations", 
                "measure": "Primary immunogenicity parameters", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01923610"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Clinic of Barcelona", 
            "investigator_full_name": "Juan A. Arnaiz", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "All grade 1 and 2 adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "28 days of vaccination"
            }, 
            {
                "description": "binding titration to the construct MVAB\nbinding titration to and neutralisation of vaccinia", 
                "measure": "Antibody responses", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "CD8/CD4+ T cell responses (ELISPOT) at week 0\nintracellular cytokine analysis at week 0, 2, 4 and 12", 
                "measure": "cellular responses", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Hospital Clinic of Barcelona", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital Clinic of Barcelona", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}